Paradigm Biocapital Advisors LP: NUVALENT INC (NUVL): Quarterly 13F Position History
As of Q1 2026, Paradigm Biocapital Advisors LP reported 5,324,433 shares of NUVALENT INC (NUVL), worth $545.5M and representing 11.1% of its 13F equity book. Quarter-over-quarter share count change: + 55,000 (+1.0%) . The position first appeared in Q2 2023 and has been disclosed across 12 13F-HR filings in Pactolio's tracked window.
- 5,324,433Shares Held (Latest Filing)
- $545.5MReported Market Value (Latest Filing)
- 11.1%Portfolio Weight (% of 13F Equity Book)
- +55,000Quarter-over-Quarter Share Change
- +$15.4MQuarter-over-Quarter Value Change
- 5,363,379Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 12 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 5,324,433 | +55,000 | +1.0% | $545.5M | 11.1% | $102.5 |
| Q4 2025 | 5,269,433 | 0 | — | $530.1M | 14.2% | $100.6 |
| Q3 2025 | 5,269,433 | 0 | — | $455.7M | 13.5% | $86.5 |
| Q2 2025 | 5,269,433 | 0 | — | $402.1M | 17.2% | $76.3 |
| Q1 2025 | 5,269,433 | 93,946 | -1.8% | $373.7M | 17.2% | $70.9 |
| Q4 2024 | 5,363,379 | +363,379 | +7.3% | $419.8M | 14.6% | $78.3 |
| Q3 2024 | 5,000,000 | +428,322 | +9.4% | $511.5M | 17.9% | $102.3 |
| Q2 2024 | 4,571,678 | +393,848 | +9.4% | $346.8M | 13.3% | $75.9 |
| Q1 2024 | 4,177,830 | +319,822 | +8.3% | $313.7M | 11.0% | $75.1 |
| Q4 2023 | 3,858,008 | +2,219,861 | +135.5% | $283.9M | 13.3% | $73.6 |
| Q3 2023 | 1,638,147 | +517,682 | +46.2% | $75.3M | 5.1% | $46.0 |
| Q2 2023 | 1,120,465 | — | — | $47.3M | 3.8% | $42.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a NUVL position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported NUVALENT INC (NUVL) on its 13F-HR filing for the period ending 2023-06-30 (Q2 2023). The position has appeared on 12 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in NUVL?
Between Q4 2025 and Q1 2026, Paradigm Biocapital Advisors LP added 55,000 shares of NUVL (+1.0%), bringing the total reported position to 5,324,433 shares at a market value of $545.5M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in NUVL?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.